Anti–PD-1 immunotherapy with or without chemo for hard-to-treat cancers
Treatments studied
Part of Cancer clinical trials.
This early-phase study tests an anti–PD-1 antibody, either alone or with decitabine or chemotherapy, in people whose cancer has come back or isn’t responding to treatment. It may help your immune system attack the cancer, especially after prior therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed cancer that has relapsed or is treatment-resistant (includes certain blood and solid cancers).
- You’re between 12 and 75 years old.
- Your general health/activity level is fairly good (ECOG score less than 2).
- Your cancer has a measurable tumor/spot that can be tracked on scans (bigger than 1 cm).
- You’ve had at least two prior chemotherapy regimens, and you’re off prior treatment for at least 4 weeks (or had stem cell transplant more than 3 months ago).
- Your blood counts and major organ function (kidney, liver, lungs, heart) meet minimum lab limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (PD-1) and chemotherapy for people with advanced head and neck cancers that are poorly differentiated. The goal is to see if the combination helps shrink tumors before possible surgery or radiation.
This trial tests a new combination of two drugs (PIN plus an anti-PD1 immunotherapy) for people with advanced solid tumors that either did not respond to standard treatment or have tumor types known to have low response to immunotherapy, like liver cancer. The goal is to see if this combination can help shrink or control the cancer.
This study looks at combining radiation therapy with immunotherapy for advanced breast cancer that has spread or cannot be surgically removed. The goal is to see if adding radiation after treatment helps improve outcomes.
This study tests a combination treatment for people with advanced solid tumors that have not responded to standard therapies. It uses a type of radiation therapy (PRaG) together with another treatment, and is specifically looking at people who have a low level of lymphocytes in their blood, which may affect how well the treatment works.
This trial tests a combination of two drugs: peginterferon α-2b (an immune-boosting drug) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). They hope the combo might work better for people with advanced solid tumors that haven't responded to other treatments.
This trial tests a new immunotherapy drug (tirellizumab) combined with chemotherapy before surgery for early-stage oral cancer. It aims to see if this combination can help shrink the tumor and improve outcomes.
Hear when a new Malignancies Multiple trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.